-
OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC
•
OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising USD 100 million. The round was led by Novo Holdings, OrbiMed, and F-Prime Capital, with significant contributions from BioTrack Capital, a Chinese investor involved in OnCusp’s seed funding, Catalio Capital Management, Marshall Wace, Forge Life…
-
Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential
•
Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna, aimed at inhibiting the creatine transport channel SLC6A8. The drug is currently undergoing Phase II trials for RAS-mutated advanced or metastatic colorectal cancer (mCRC). The agreement also encompasses additional follow-on compounds targeting SLC6A8. In return…
-
Boehringer Ingelheim Teams Up with 3T Biosciences for Next-Gen T-Cell Cancer Therapies
•
German pharmaceutical leader Boehringer Ingelheim (BI) has entered into a new agreement with U.S.-based 3T Biosciences to advance next-generation T-cell-based immuno-oncology therapies. BI will contribute its proprietary patient-derived T-cell receptor (TCR) data to help identify binding antigens using 3T’s discovery platform. Under the terms, BI will provide an undisclosed upfront…
-
Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances
•
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces with biotech incubator Flagship Pioneering to drive pre-clinical breakthroughs for cardiometabolic disorders. This collaboration marks the initial phase of a strategic alliance inked in 2022, spotlighting novel therapeutics for cardiometabolic and rare diseases. As part…
-
Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with China’s Insilico Medicine to develop a KAT6A inhibitor originating from Insilico’s AI-driven platform. The candidate, targeted for hormone-sensitive cancers and other oncological indications, shows promise as a potent KAT6A inhibitor based on preclinical data. KAT6A,…
-
Genrix Bio Seeks China Approval for New Xeligekimab Use in Axial Spondyloarthritis
•
Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443), a biopharmaceutical company based in China, has submitted a new indication filing for its innovative biologic product xeligekimab, which has now been accepted for review by the National Medical Products Administration (NMPA). This latest filing seeks approval for xeligekimab to treat radiologically…
-
Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate
•
The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical & Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), for monopolistic pricing practices, this time concerning the injection product polymyxin B sulfate. The Chinese company has pledged to…
-
Akeso Biopharma Submits New Indication Application for Cadonilimab in Gastric Cancer Treatment
•
Akeso Biopharma (HKG: 9926), a leading biopharmaceutical company based in China, has announced the submission of a new indication supplementary approval filing for its bispecific antibody (BsAb) drug candidate, cadonilimab (AK104). The company is seeking to expand the use of cadonilimab in combination with chemotherapy as a first-line treatment for…
